AbbVie has completed a Phase 3 trial assessing BOTOX (botulinum toxin Type A) injections for masseter muscle prominence in adults. The trial, sponsored by AbbVie, has reached completion status, supporting the company's supplemental Biologics License Application (sBLA) filed with the FDA for this cosmetic indication.
Regulatory
BOTOX Masseter Indication Moves Closer to FDA OK
AbbVie's sBLA for jawline prominence shows completed trial data.
1-YEAR MOVE
ABBV
▲11.6%
| Ticker | Company | 1-year change |
|---|---|---|
| ABBV | AbbVie (Allergan Aesthetics) | +11.6% |
BOTOX would be the first neurotoxin cleared for masseter prominence if approved.
Masseter reduction via botulinum toxin is already widely practiced off-label—practitioners inject 20–50 units per side to soften jawline prominence and reduce bruxism-related hypertrophy. Formal FDA approval would make BOTOX the first and only neurotoxin cleared for this specific use, creating a significant marketing and reimbursement advantage over Dysport and Jeuveau. Approval could unlock a new patient segment seeking non-surgical jawline refinement, particularly in Asian markets where masseter prominence is a top aesthetic concern. Timeline to decision remains unclear, but completion of the trial removes a major regulatory hurdle.
Source: original report ↗
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.